CY2021008I1 - 5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδινο-2-υλο καρβοξαμιδια ως αναστολεις jak - Google Patents

5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδινο-2-υλο καρβοξαμιδια ως αναστολεις jak

Info

Publication number: CY2021008I1
Authority: CY; Cyprus
Prior art keywords: pyridino; carboxamides; triazolo; phenyl; jak inhibitors
Prior art date: 2009-06-26

Application number

CY2021008C

Other languages

English (en)

Other versions

CY2021008I2 (el

Original Assignee

Galapagos N.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-06-26

Filing date

2021-03-29

Publication date

2021-05-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42562363&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2021008(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2021-03-29 Application filed by Galapagos N.V. filed Critical Galapagos N.V.

2021-05-05 Publication of CY2021008I1 publication Critical patent/CY2021008I1/el

2021-06-25 Publication of CY2021008I2 publication Critical patent/CY2021008I2/el

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Oncology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Transplantation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CY2008021C 2009-06-26 2021-03-29 Πυριμιδινες οι οποιες παρεμποδιζουν την ανατυπωση ηιv CY2021008I2 (el)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US22068809P	2009-06-26	2009-06-26
EP10724881.7A EP2445911B1 (en)	2009-06-26	2010-06-25	5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors
PCT/EP2010/059064 WO2010149769A1 (en)	2009-06-26	2010-06-25	5-phenyl-[1,2,4 ]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors

Publications (2)

Publication Number	Publication Date
CY2021008I1 true CY2021008I1 (el)	2021-05-05
CY2021008I2 CY2021008I2 (el)	2021-06-25

Family

ID=42562363

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20171100569T CY1119214T1 (el)	2009-06-26	2017-05-31	5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδινο-2-υλο καρβοξαμιδια ως αναστολεις jak
CY20201100020T CY1122649T1 (el)	2009-06-26	2020-01-09	5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδιν-2-υλο καρβοξαμιδια ως jak αναστολεις
CY2008021C CY2021008I2 (el)	2009-06-26	2021-03-29	Πυριμιδινες οι οποιες παρεμποδιζουν την ανατυπωση ηιv

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
CY20171100569T CY1119214T1 (el)	2009-06-26	2017-05-31	5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδινο-2-υλο καρβοξαμιδια ως αναστολεις jak
CY20201100020T CY1122649T1 (el)	2009-06-26	2020-01-09	5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδιν-2-υλο καρβοξαμιδια ως jak αναστολεις

Country Status (43)

Country	Link
US (9)	US8088764B2 (el)
EP (2)	EP3178819B1 (el)
JP (2)	JP5591925B2 (el)
KR (3)	KR101696669B1 (el)
CN (2)	CN102482273B (el)
AR (1)	AR077220A1 (el)
AU (3)	AU2010264633B2 (el)
BR (1)	BRPI1015569B8 (el)
CA (1)	CA2765985C (el)
CL (1)	CL2011003247A1 (el)
CO (1)	CO6491040A2 (el)
CR (1)	CR20120016A (el)
CY (3)	CY1119214T1 (el)
DK (2)	DK3178819T3 (el)
DO (1)	DOP2011000388A (el)
EA (1)	EA021637B1 (el)
EC (1)	ECSP12011626A (el)
ES (2)	ES2626908T3 (el)
FR (1)	FR21C1011I2 (el)
GB (1)	GB2483424B (el)
HR (2)	HRP20170826T1 (el)
HU (3)	HUE047478T2 (el)
IL (1)	IL216667A (el)
LT (3)	LT3178819T (el)
MA (1)	MA33448B1 (el)
ME (1)	ME02699B (el)
MX (1)	MX344951B (el)
MY (1)	MY156664A (el)
NI (1)	NI201100222A (el)
NL (1)	NL301096I2 (el)
NO (1)	NO2021013I1 (el)
NZ (1)	NZ596838A (el)
PE (1)	PE20121032A1 (el)
PL (2)	PL2445911T3 (el)
PT (2)	PT3178819T (el)
RS (1)	RS56035B1 (el)
SG (2)	SG10201703497YA (el)
SI (2)	SI3178819T1 (el)
SM (1)	SMT201700265T1 (el)
TW (1)	TWI462920B (el)
UA (1)	UA107935C2 (el)
WO (1)	WO2010149769A1 (el)
ZA (1)	ZA201109386B (el)

Families Citing this family (88)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
TWI462920B (zh) *	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
JO3030B1 (ar) *	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
WO2011039638A2 (en)	2009-10-02	2011-04-07	Foamix Ltd.	Topical tetracycline compositions
EP2343294A1 (en)	2009-11-30	2011-07-13	Bayer Schering Pharma AG	Substituted triazolopyridines
AR086042A1 (es) *	2011-04-28	2013-11-13	Galapagos Nv	Compuesto util para el tratamiento de enfermedades degenerativas e inflamatorias y composicion farmaceutica
EP2770992A4 (en) *	2011-10-26	2015-12-30	Emily A Stein	AGENTS, METHODS AND DEVICES FOR AFFECTING NERVOUS FUNCTION
US20130310340A1 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
WO2013189771A1 (en)	2012-06-22	2013-12-27	Galapagos Nv	Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
GB201302036D0 (en) *	2013-02-05	2013-03-20	Queen Mary & Westfield College	Diagnosis
EP3079694A1 (en) *	2013-12-11	2016-10-19	Cephalon, Inc.	Treatment of multiple sclerosis with a 1,2,4-triazolo [1,5a]pyridine derivative
GB201402070D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Pharmaceutical compositions for the treatment of inflammatory disorders
GB201402071D0 (en)	2014-02-07	2014-03-26	Galapagos Nv	Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders
TWI679205B (zh)	2014-09-02	2019-12-11	日商日本新藥股份有限公司	吡唑并噻唑化合物及醫藥
MA41252A (fr)	2014-12-23	2017-10-31	Gilead Sciences Inc	Formes solides d'un inhibiteur d'ask 1
MX386902B (es) *	2015-04-13	2025-03-19	Alfasigma Spa	Metodos para el tratamiento de trastornos cardiovasculares.
BR112017021583A2 (pt) *	2015-04-13	2018-07-03	Galapagos Nv	métodos para o tratamento de transtornos inflamatórios
AU2016257892A1 (en) *	2015-05-05	2017-11-09	Concert Pharmaceuticals, Inc.	Deuterated filgotinib
CN105061420B (zh) *	2015-06-04	2017-09-05	南京旗昌医药科技有限公司	一种jak抑制剂的晶型及其制备方法和应用
CN104987333B (zh) *	2015-07-14	2017-01-11	苏州富士莱医药股份有限公司	一种Filgotinib的合成方法
WO2017012770A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Acid addition salts of filgotinib
WO2017012773A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Solid forms of filgotinib free base
WO2017012771A1 (en)	2015-07-23	2017-01-26	Ratiopharm Gmbh	Crystalline filgotinib sulfonic acid addition salts
CN105198880B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物a晶型及其制备方法
CN105198877B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物g晶型及其制备方法
CN105198879B (zh) *	2015-09-18	2017-09-22	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物c晶型及其制备方法
CN105111207B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物d晶型及其制备方法
CN105198878B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物f晶型及其制备方法
CN105111206B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物e晶型及其制备方法
CN105218539B (zh) *	2015-09-18	2017-07-25	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物b晶型及其制备方法
CN105198876B (zh) *	2015-09-18	2017-09-29	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物h晶型及其制备方法
US20170173034A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a syk inhibitor for treating cancers and inflammatory disorders
WO2017106568A1 (en) *	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and a bromodomain inhibitor for treating cancer
US20170174788A1 (en)	2015-12-17	2017-06-22	Gilead Sciences, Inc.	Combination of a jak inhibitor and an mmp9 binding protein for treating inflammatory disorders
CN112851682B (zh) *	2016-02-02	2022-10-25	深圳市塔吉瑞生物医药有限公司	一种取代的吡啶酰胺类化合物及其应用
TWI712604B (zh) *	2016-03-01	2020-12-11	日商日本新藥股份有限公司	具jak抑制作用之化合物之結晶
CN105669669A (zh) *	2016-03-04	2016-06-15	上海宣创生物科技有限公司	一种环丙烷甲酰胺衍生物的a晶型、b晶型、d晶型、g晶型和m晶型及其制备方法
MX2018011422A (es) *	2016-03-21	2019-07-08	Crystal Pharmatech Co Ltd	Farmaco de sal cristalina de clorhidrato para tratar o prevenir enfermedad asociada con janus cinasas (jak) y su metodo de preparacion.
US10071079B2 (en)	2016-06-29	2018-09-11	Bristol-Myers Squibb Company	[1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
KR102492378B1 (ko)	2016-07-26	2023-01-27	톈진 롱보진 파마시우티컬 씨오., 엘티디.	선택적 jak 저해제로서 화합물, 및 이의 염 및 치료학적 용도
EP3490983B1 (en)	2016-07-30	2021-02-17	Bristol-Myers Squibb Company	Dimethoxyphenyl substituted indole compounds as tlr7, tlr8 or tlr9 inhibitors
CN107759587B (zh) *	2016-08-19	2021-01-26	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
MX2020012139A (es)	2016-09-08	2021-01-29	Vyne Pharmaceuticals Inc	Composiciones y metodos para tratar rosacea y acne.
US10660877B2 (en)	2016-09-09	2020-05-26	Bristol-Myers Squibb Company	Pyridyl substituted indole compounds
CN107880038B (zh) *	2016-09-30	2021-09-28	中国医药研究开发中心有限公司	[1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CA3043396A1 (en)	2016-11-10	2018-05-17	Galapagos Nv	Compounds and pharmaceutical compositions thereof for the treatment of inflammatory diseases
EA039344B1 (ru) *	2017-01-19	2022-01-17	Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд.	Гетероциклическое соединение в качестве ингибитора jak и его соли и терапевтическое применение
GB201702603D0 (en)	2017-02-17	2017-04-05	Galápagos Nv	Novel compositions and pharmaceutical compositions thereof for the treatment of inflammatory disorders
JOP20180018A1 (ar)	2017-03-14	2019-01-30	Gilead Sciences Inc	تركيبات صيدلية تتضمن مثبط jak
KR102688509B1 (ko)	2017-08-04	2024-07-24	브리스톨-마이어스 스큅 컴퍼니	[1,2,4]트리아졸로[4,3-a]피리디닐 치환된 인돌 화합물
WO2019028302A1 (en)	2017-08-04	2019-02-07	Bristol-Myers Squibb Company	SUBSTITUTED INDOLE COMPOUNDS USEFUL AS TLR7 / 8/9 INHIBITORS
EP3710440B1 (en)	2017-11-14	2023-04-05	Bristol-Myers Squibb Company	Substituted indole compounds
CN111527080B (zh)	2017-12-15	2023-09-22	百时美施贵宝公司	取代的吲哚醚化合物
DK3728252T3 (da)	2017-12-18	2023-11-13	Bristol Myers Squibb Co	4-azaindolforbindelser
CN111491930B (zh)	2017-12-19	2023-09-26	百时美施贵宝公司	可用作tlr抑制剂的经取代的吲哚化合物
SG11202005700SA (en)	2017-12-19	2020-07-29	Bristol Myers Squibb Co	Amide substituted indole compounds useful as tlr inhibitors
SG11202005704RA (en)	2017-12-19	2020-07-29	Bristol Myers Squibb Co	6-azaindole compounds
MX2020006014A (es)	2017-12-20	2020-08-17	Bristol Myers Squibb Co	Compuestos de diazaindol.
CA3086431A1 (en)	2017-12-20	2019-06-27	Bristol-Myers Squibb Company	Amino indole compounds useful as tlr inhibitors
US11420958B2 (en)	2017-12-20	2022-08-23	Bristol-Myers Squibb Company	Aryl and heteroaryl substituted indole compounds
GB201808575D0 (en) *	2018-05-24	2018-07-11	Galapagos Nv	Methods for the treatment of psoriatic arthrits
US10815227B2 (en)	2018-08-27	2020-10-27	Cadila Healthcare Limited	Processes for the preparation of filgotinib
JP7597710B2 (ja)	2018-10-24	2024-12-10	ブリストル－マイヤーズスクイブカンパニー	置換インドール二量体の化合物
KR102839382B1 (ko)	2018-10-24	2025-07-25	브리스톨-마이어스 스큅 컴퍼니	치환된 인돌 및 인다졸 화합물
CN111154711B (zh) *	2018-11-07	2022-08-05	杭州瑞普晨创科技有限公司	JAK2抑制剂在胰岛β细胞诱导分化中的应用
WO2020177705A1 (zh) *	2019-03-05	2020-09-10	苏州科睿思制药有限公司	Filgotinib的马来酸盐晶型CSI及其制备方法和用途
CN113631557B (zh)	2019-03-14	2024-03-15	上海华汇拓医药科技有限公司	Jak激酶抑制剂及其制备方法和在医药领域的应用
CN114364798A (zh)	2019-03-21	2022-04-15	欧恩科斯欧公司	用于治疗癌症的Dbait分子与激酶抑制剂的组合
BR112021019087A2 (pt) *	2019-03-30	2021-11-30	Unichem Lab Ltd	Novo processo para a preparação de filgotinibe e intermediários do mesmo
WO2020227484A1 (en)	2019-05-09	2020-11-12	Bristol-Myers Squibb Company	Substituted benzimidazolone compounds
CN110204542B (zh) *	2019-05-23	2022-05-20	四川伊诺达博医药科技有限公司	一种JAK1抑制剂Filgotinib的合成方法
CN110151738A (zh) *	2019-06-03	2019-08-23	上海基科生物化学有限公司	一种Jak2抑制剂联合虎杖苷雾化剂及其制备方法和应用
EP4041730A1 (en)	2019-10-01	2022-08-17	Bristol-Myers Squibb Company	Substituted bicyclic heteroaryl compounds
EP4038059B1 (en)	2019-10-04	2023-09-20	Bristol-Myers Squibb Company	Substituted carbazole compounds
IT201900020240A1 (it)	2019-11-04	2021-05-04	Advitech Advisory And Tech Sa	Procedimento per la preparazione di Filgotinib e intermedi di sintesi
US20220401436A1 (en)	2019-11-08	2022-12-22	INSERM (Institute National de la Santé et de la Recherche Médicale)	Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
CN110878097B (zh) *	2019-11-29	2021-11-02	杭州科巢生物科技有限公司	菲格替尼的制备方法
CN111072655B (zh) *	2019-12-30	2021-12-10	深圳市坤健创新药物研究院	一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use
JP7395762B2 (ja) *	2020-02-13	2023-12-11	チューハイユナイテッドラボラトリーズシーオー．，エルティーディー．	Ｊａｋキナーゼ関連疾患の治療のための薬物の調製におけるｊａｋ阻害剤の使用
RS67023B1 (sr)	2020-02-21	2025-08-29	Zhuhai United Laboratories Co Ltd	Kristalni oblik inhibitora jak i njegova primena
WO2022039850A1 (en) *	2020-08-17	2022-02-24	Vyne Therapeutics Inc.	Tofacitinib-containing anhydrous elastomer-based gel formulations
WO2022072238A1 (en) *	2020-10-02	2022-04-07	University Of Massachusetts	Targeting polycythemia vera (pv)-initiating cells by blocking leukotriene binding to their receptors
CN115368389A (zh) *	2021-05-19	2022-11-22	奥锐特药业(天津)有限公司	一种Filgotinib中间体的制备方法
CN113773322B (zh) *	2021-11-10	2022-02-11	奥锐特药业(天津)有限公司	一种Filgotinib的制备方法
CN114409675B (zh) *	2022-01-07	2023-08-04	重庆医科大学	螺环异恶唑酮色满衍生物在制备用于治疗jak1介导的疾病药物中的用途
CN116496268A (zh) *	2022-01-18	2023-07-28	盛世泰科生物医药技术(苏州)有限公司	一种含环丙酰胺化合物及其应用
WO2023194842A1 (en)	2022-04-05	2023-10-12	Unichem Laboratories Limited	Substituted tricyclic compounds and their use in rheumatoid arthritis

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ208996A (en)	1983-07-28	1989-08-29	American Cyanamid Co	5-substituted(1,2,4 triazpyrimidin-2-amine derivatives and pharmaceutical compositions
WO2000044722A1 (en)	1999-01-29	2000-08-03	Chugai Seiyaku Kabushiki Kaisha	Chondrongenesis promotors and indolin-2-one derivatives
WO2002087620A1 (en)	2001-04-27	2002-11-07	Chugai Seiyaku Kabushiki Kaisha	Chondrogenesis promoters
US6514989B1 (en) *	2001-07-20	2003-02-04	Hoffmann-La Roche Inc.	Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives
ATE334131T1 (de)	2003-02-14	2006-08-15	Pfizer Prod Inc	Triazolopyridine als entzündungshemmende verbindungen
US20050222171A1 (en)	2004-01-22	2005-10-06	Guido Bold	Organic compounds
JP2008503712A (ja)	2004-06-21	2008-02-07	ガラパゴス・ナムローゼ・フェンノートシャップ	骨関節炎治療の方法及び手段
MX2007002050A (es)	2004-08-18	2007-03-29	Pharmacia & Upjohn Co Llc	Compuestos de triazolopiridina.
MX2007004179A (es)	2004-10-07	2007-06-07	Warner Lambert Co	Derivados de triazolpiridina como agentes antibacterianos.
GB0515026D0 (en)	2005-07-21	2005-08-31	Novartis Ag	Organic compounds
JP5336375B2 (ja)	2006-08-30	2013-11-06	セルゾームリミテッド	キナーゼ阻害剤としてのトリアゾール誘導体
TW200904816A (en)	2007-06-05	2009-02-01	Takeda Pharmaceutical	Fused heterocycle derivatives and use thereof
MX2010000716A (es)	2007-07-18	2010-03-26	Novartis Ag	Compuestos de heteroarilo biciclicos y su uso como inhibidores de cinasa.
WO2009017954A1 (en) *	2007-08-01	2009-02-05	Phenomix Corporation	Inhibitors of jak2 kinase
MX2010002312A (es)	2007-08-31	2010-03-18	Merck Serono Sa	Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis.
GB0719803D0 (en) *	2007-10-10	2007-11-21	Cancer Rec Tech Ltd	Therapeutic compounds and their use
JP5595389B2 (ja)	2008-06-20	2014-09-24	ジェネンテック，インコーポレイテッド	トリアゾロピリジンｊａｋ阻害剤化合物と方法
US20100048557A1 (en)	2008-06-20	2010-02-25	Bing-Yan Zhu	Triazolopyridine JAK Inhibitor Compounds and Methods
WO2010010187A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010184A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	[1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors
WO2010010189A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
JO3041B1 (ar)	2008-07-25	2016-09-05	Galapagos Nv	مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
WO2010010186A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases
WO2010010188A1 (en)	2008-07-25	2010-01-28	Galapagos Nv	Novel compounds useful for the treatment of degenerative and inflammatory diseases.
AU2010254806C1 (en)	2009-06-05	2016-07-07	Cephalon, Inc.	Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives
JO3030B1 (ar)	2009-06-26	2016-09-05	Galapagos Nv	مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات
TWI462920B (zh) *	2009-06-26	2014-12-01	葛萊伯格有限公司	用於治療退化性及發炎疾病之新穎化合物
US20130310340A1 (en)	2012-05-16	2013-11-21	Rigel Pharmaceuticals, Inc.	Method of treating muscular degradation
WO2013189771A1 (en)	2012-06-22	2013-12-27	Galapagos Nv	Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof

2010
- 2010-06-23 TW TW099120586A patent/TWI462920B/zh active
- 2010-06-24 AR ARP100102235A patent/AR077220A1/es active IP Right Grant
- 2010-06-25 HR HRP20170826TT patent/HRP20170826T1/hr unknown
- 2010-06-25 GB GB1200457.8A patent/GB2483424B/en not_active Expired - Fee Related
- 2010-06-25 SG SG10201703497YA patent/SG10201703497YA/en unknown
- 2010-06-25 UA UAA201200745A patent/UA107935C2/ru unknown
- 2010-06-25 PL PL10724881T patent/PL2445911T3/pl unknown
- 2010-06-25 KR KR1020127001940A patent/KR101696669B1/ko active Active
- 2010-06-25 KR KR1020187010516A patent/KR101916194B1/ko active Active
- 2010-06-25 LT LTEP17152084.4T patent/LT3178819T/lt unknown
- 2010-06-25 HU HUE17152084A patent/HUE047478T2/hu unknown
- 2010-06-25 MA MA34556A patent/MA33448B1/fr unknown
- 2010-06-25 EP EP17152084.4A patent/EP3178819B1/en active Active
- 2010-06-25 RS RS20170532A patent/RS56035B1/sr unknown
- 2010-06-25 WO PCT/EP2010/059064 patent/WO2010149769A1/en not_active Ceased
- 2010-06-25 US US12/823,654 patent/US8088764B2/en active Active
- 2010-06-25 ME MEP-2017-122A patent/ME02699B/me unknown
- 2010-06-25 PE PE2011002153A patent/PE20121032A1/es active IP Right Grant
- 2010-06-25 DK DK17152084.4T patent/DK3178819T3/da active
- 2010-06-25 AU AU2010264633A patent/AU2010264633B2/en active Active
- 2010-06-25 PL PL17152084T patent/PL3178819T3/pl unknown
- 2010-06-25 PT PT171520844T patent/PT3178819T/pt unknown
- 2010-06-25 EP EP10724881.7A patent/EP2445911B1/en active Active
- 2010-06-25 PT PT107248817T patent/PT2445911T/pt unknown
- 2010-06-25 JP JP2012516761A patent/JP5591925B2/ja active Active
- 2010-06-25 KR KR1020177000585A patent/KR101850716B1/ko active Active
- 2010-06-25 ES ES10724881.7T patent/ES2626908T3/es active Active
- 2010-06-25 HU HUE10724881A patent/HUE033154T2/en unknown
- 2010-06-25 MX MX2011013450A patent/MX344951B/es active IP Right Grant
- 2010-06-25 SI SI201031962T patent/SI3178819T1/sl unknown
- 2010-06-25 CN CN201080028631.4A patent/CN102482273B/zh active Active
- 2010-06-25 CA CA2765985A patent/CA2765985C/en active Active
- 2010-06-25 SM SM20170265T patent/SMT201700265T1/it unknown
- 2010-06-25 MY MYPI2011006263A patent/MY156664A/en unknown
- 2010-06-25 BR BRPI1015569A patent/BRPI1015569B8/pt active IP Right Grant
- 2010-06-25 SG SG2011096211A patent/SG177363A1/en unknown
- 2010-06-25 EA EA201270075A patent/EA021637B1/ru unknown
- 2010-06-25 CN CN201410408911.8A patent/CN104262337A/zh active Pending
- 2010-06-25 SI SI201031467A patent/SI2445911T1/sl unknown
- 2010-06-25 LT LTEP10724881.7T patent/LT2445911T/lt unknown
- 2010-06-25 DK DK10724881.7T patent/DK2445911T3/en active
- 2010-06-25 ES ES17152084T patent/ES2766573T3/es active Active
- 2010-06-25 NZ NZ596838A patent/NZ596838A/en unknown
2011
- 2011-11-29 IL IL216667A patent/IL216667A/en active IP Right Grant
- 2011-12-02 US US13/310,090 patent/US8563545B2/en active Active
- 2011-12-14 DO DO2011000388A patent/DOP2011000388A/es unknown
- 2011-12-20 ZA ZA2011/09386A patent/ZA201109386B/en unknown
- 2011-12-21 NI NI201100222A patent/NI201100222A/es unknown
- 2011-12-21 CL CL2011003247A patent/CL2011003247A1/es unknown
2012
- 2012-01-11 CR CR20120016A patent/CR20120016A/es unknown
- 2012-01-16 CO CO12005379A patent/CO6491040A2/es active IP Right Grant
- 2012-01-26 EC EC2012011626A patent/ECSP12011626A/es unknown
2013
- 2013-09-13 US US14/026,027 patent/US8999979B2/en active Active
2014
- 2014-07-30 JP JP2014154379A patent/JP2014221825A/ja not_active Withdrawn
2015
- 2015-04-02 US US14/677,058 patent/US9309244B2/en active Active
- 2015-08-28 AU AU2015218544A patent/AU2015218544B2/en active Active
2016
- 2016-04-11 US US15/095,317 patent/US9707237B2/en active Active
2017
- 2017-05-31 CY CY20171100569T patent/CY1119214T1/el unknown
- 2017-07-10 AU AU2017204744A patent/AU2017204744A1/en not_active Abandoned
- 2017-07-17 US US15/651,116 patent/US10328081B2/en active Active
2019
- 2019-05-09 US US16/407,593 patent/US11000528B2/en active Active
2020
- 2020-01-09 CY CY20201100020T patent/CY1122649T1/el unknown
- 2020-01-09 HR HRP20200033TT patent/HRP20200033T1/hr unknown
2021
- 2021-03-03 FR FR21C1011C patent/FR21C1011I2/fr active Active
- 2021-03-04 HU HUS2100007C patent/HUS2100007I1/hu unknown
- 2021-03-17 NL NL301096C patent/NL301096I2/nl unknown
- 2021-03-19 LT LTPA2021504C patent/LTC2445911I2/lt unknown
- 2021-03-23 NO NO2021013C patent/NO2021013I1/no unknown
- 2021-03-29 CY CY2008021C patent/CY2021008I2/el unknown
- 2021-04-14 US US17/230,483 patent/US12042498B2/en active Active
2024
- 2024-06-13 US US18/741,974 patent/US20240325405A1/en active Pending

Also Published As

Publication number	Publication date
BRPI1015569B1 (pt)	2020-10-27
EP2445911B1 (en)	2017-03-01
SI2445911T1 (sl)	2017-07-31
JP2014221825A (ja)	2014-11-27
RS56035B1 (sr)	2017-09-29
SI3178819T1 (sl)	2020-02-28
NL301096I2 (nl)	2021-04-12
US8088764B2 (en)	2012-01-03
MX2011013450A (es)	2012-05-08
JP2012530766A (ja)	2012-12-06
EP2445911A1 (en)	2012-05-02
AU2017204744A1 (en)	2017-07-27
KR101850716B1 (ko)	2018-04-20
US20120142678A1 (en)	2012-06-07
EP3178819B1 (en)	2019-12-04
CA2765985A1 (en)	2010-12-29
DOP2011000388A (es)	2012-04-15
GB201200457D0 (en)	2012-02-22
DK2445911T3 (en)	2017-06-06
CN102482273A (zh)	2012-05-30
AU2015218544A1 (en)	2015-09-17
MX344951B (es)	2017-01-12
SG177363A1 (en)	2012-02-28
CY1122649T1 (el)	2021-03-12
NO2021013I1 (no)	2021-03-23
CO6491040A2 (es)	2012-07-31
PT2445911T (pt)	2017-06-12
US20160296530A1 (en)	2016-10-13
US20200078365A1 (en)	2020-03-12
EP3178819A1 (en)	2017-06-14
HUE047478T2 (hu)	2020-04-28
FR21C1011I1 (el)	2021-05-07
SG10201703497YA (en)	2017-06-29
US9309244B2 (en)	2016-04-12
US20100331319A1 (en)	2010-12-30
LT2445911T (lt)	2017-06-12
US20210369727A1 (en)	2021-12-02
US12042498B2 (en)	2024-07-23
IL216667A0 (en)	2012-02-29
EA021637B1 (ru)	2015-07-30
HUE033154T2 (en)	2017-11-28
BRPI1015569B8 (pt)	2021-05-25
AR077220A1 (es)	2011-08-10
HUS2100007I1 (hu)	2021-03-29
CA2765985C (en)	2017-06-06
US11000528B2 (en)	2021-05-11
ECSP12011626A (es)	2012-02-29
UA107935C2 (xx)	2015-03-10
ES2766573T3 (es)	2020-06-12
KR20180041262A (ko)	2018-04-23
KR20170007534A (ko)	2017-01-18
PL3178819T3 (pl)	2020-04-30
MA33448B1 (fr)	2012-07-03
US20180000831A1 (en)	2018-01-04
HRP20200033T1 (hr)	2020-03-20
AU2010264633A1 (en)	2011-12-22
WO2010149769A1 (en)	2010-12-29
PT3178819T (pt)	2020-01-21
US8999979B2 (en)	2015-04-07
KR20120107919A (ko)	2012-10-04
FR21C1011I2 (fr)	2022-03-25
AU2015218544B2 (en)	2017-04-27
US10328081B2 (en)	2019-06-25
HK1167403A1 (en)	2012-11-30
HRP20170826T1 (hr)	2017-08-25
LTC2445911I2 (lt)	2022-09-26
US8563545B2 (en)	2013-10-22
US20150274722A1 (en)	2015-10-01
TW201103936A (en)	2011-02-01
CN104262337A (zh)	2015-01-07
TWI462920B (zh)	2014-12-01
BRPI1015569A2 (pt)	2016-08-16
CR20120016A (es)	2012-02-09
NZ596838A (en)	2014-01-31
IL216667A (en)	2015-08-31
CY1119214T1 (el)	2018-02-14
SMT201700265T1 (it)	2017-07-18
ME02699B (me)	2017-10-20
US9707237B2 (en)	2017-07-18
ZA201109386B (en)	2012-08-29
AU2010264633B2 (en)	2015-06-04
CL2011003247A1 (es)	2012-04-13
LTPA2021504I1 (lt)	2021-04-12
GB2483424A (en)	2012-03-07
MY156664A (en)	2016-03-15
PL2445911T3 (pl)	2017-08-31
US20140100220A1 (en)	2014-04-10
CY2021008I2 (el)	2021-06-25
JP5591925B2 (ja)	2014-09-17
NL301096I1 (el)	2021-03-24
KR101916194B1 (ko)	2018-11-07
GB2483424B (en)	2012-07-18
DK3178819T3 (en)	2020-01-27
NI201100222A (es)	2012-07-27
CN102482273B (zh)	2014-09-17
KR101696669B1 (ko)	2017-01-16
US20240325405A1 (en)	2024-10-03
PE20121032A1 (es)	2012-08-25
EA201270075A1 (ru)	2012-12-28
ES2626908T3 (es)	2017-07-26
LT3178819T (lt)	2020-01-27

Publication	Publication Date	Title
CY2021008I1 (el)	2021-05-05	5-φαινυλο-[1,2,4]τριαζολο[1,5-α]πυριδινο-2-υλο καρβοξαμιδια ως αναστολεις jak
IL219916A0 (en)	2012-07-31	Imidazopyridine derivatives as jak inhibitor
EP2391627A4 (en)	2012-07-18	BICYCLIC PYRAZOLO HETEROCYCLES
BR112012029437A2 (pt)	2017-03-07	derivados de pirrolo[2,3-b]pirazina-7-carboxamida e seu uso como inibidores de jak e syk
BRPI1010197A2 (pt)	2016-03-29	métodos e compostos de pirazolopirimidina jak
ZA201108541B (en)	2018-11-28	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1hpyrazol-1yl]octane-or heptane-nitrile as jak inhibitors
IL220086A0 (en)	2012-09-24	Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
ZA201302128B (en)	2014-08-27	4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (bace)
IL216145A0 (en)	2012-01-31	Dihydropyrimidinones for use as bace2 inhibitors
IL228158A0 (en)	2013-11-25	History of 7,6-dihydro-pyrazolo[5,1-a]pyrazine-4-ylamine used as betascartase inhibitors
BR112013022917A2 (pt)	2016-12-06	derivados 3,4-dihidro-pirrolo[1,2-a]pirazino-1-ilamina úteis como inibidores de beta-secretase (bace)
BRPI1008850A2 (pt)	2016-03-15	[1,2,4]triazolo[1,5-a]piridinas como inibidores de quinase
BRPI1011066A2 (pt)	2017-03-21	"pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
ZA201304646B (en)	2014-12-23	5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (bace)
IL224178A (en)	2015-07-30	Heterogeneous history of cervix as hcv inhibitors
EP2739627A4 (en)	2015-01-21	2,3-DIHYDROIMIDAZO [1,2-C] PYRIMIDIN-5 (1H) -ONE COMPOUNDS AND USE AS INHIBITORS OF LP-PLA2
IL229993A (en)	2015-10-29	8 - Alkoxy [1,2,4] triazolo [5,1 – c] pyrimidine– 2
HK1167403B (en)	2013-04-05	5-phenyl-[1,2,4]triazolo[1,5-a]pyridin-2-yl carboxamides as jak inhibitors